Cyxone files patent application to extend exclusivity of Rabeximod
Cyxone (publ.) announced today that the company has filed for an extended patent protection of Rabeximod with the European Patent Office (EPO), that will be extended to other territories in due course. An approval of the application will strengthen the company’s intellectual property portfolio and generate a longer market exclusivity for Rabeximod.Cyxone develops Rabeximod, a potentially disease modifying drug candidate for chronic diseases of the immune system as well as for critical conditions such as virally induced acute respiratory disorders. The candidate drug is subject to two